Determination of colistin A and colistin B in human plasma by UPLC-ESI high resolution tandem MS: Application to a pharmacokinetic study

Journal of Pharmaceutical and Biomedical Analysis

Volumn 83, Issue , 2013, Pages 228-236

  Gikas, Evangelos ^a,b   Bazoti, Fotini N ^a   Katsimardou, Marina ^b   Anagnostopoulos, Dimitrios ^a   Papanikolaou, Konstantinos ^c   Inglezos, Ilias ^b   Skoutelis, Athanasios ^c   Daikos, Georgios L ^b   Tsarbopoulos, Anthony ^a,d  

^a Goulandris Natural History Museum   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Colistin; Human plasma; Quantification; Tandem mass spectrometry; Ultra performance liquid chromatography

Indexed keywords

ACETIC ACID; COLISTIN; COLISTIN A; COLISTIN B; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DETERMINATION; DRUG HALF LIFE; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; FREEZE THAWING; HUMAN; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLISTIN; HUMANS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84879381598     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.05.008     Document Type: Article

References (23)

1. Bergen P.J., Li J., Rayner C.R., Nation R.L. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2006, 50:1953-1958.
2. Li J., Nation R.L., Turnidge J.D., Milne R.W., Coulthard K., Rayner C.R., Paterson D.L. Colistin: the re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect. Dis. 2006, 6:589-601.
3. Koyama Y., Kurosawa A., Tsuchiya A., et al. A new antibiotic, colistin, produced by spore-forming soil bacteria. J. Antibiot. Tokyo 1950, 3:457-458.
4. Elwood C.M., Lucas G.D., Muehrcke R.C. Acute renal failure associated with sodium colistimethate treatment. Arch. Intern. Med. 1966, 118:326-334.
5. Hartzell J.D., Neff R., Ake J., et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis. 2009, 48:1724-1728.
6. Koch-Weser J., Sidel V.W., Federman E.B., Kanarek P., Finer D.C., Eaton A.E. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann. Intern. Med. 1970, 72:857-868.
7. Wolinsky E., Hines J.D. Neurotoxic and nephrotoxic effects of colistin patients with renal disease. N. Engl. J. Med. 1962, 266:759.
8. Garnacho-Montero J., Ortiz-Leyba C., Jiménez-Jiménez F.J., et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin. Infect. Dis. 2003, 36:1111-1118.
9. Linden P.K., Kusne S., Coley K., et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin. Infect. Dis. 2003, 37:e154-e160.
10. Benifla M., Zucker G., Cohen S., Alkan M. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin. J. Antimicrob. Chemother. 2004, 54:290-293.
11. Michalopoulos A.S., Tsiodras S., Rellos K., et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin. Microbiol. Infect. 2005, 11:115-121.
12. Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr. Opin. Pulm. Med. 2001, 7:434-440.
13. Hogg G.M., Barr J.G., Webb C.H. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J. Antimicrob. Chemother. 1998, 41:494-495.
14. Giamarellos-Bourboulis E.J., Sambatakou H., Galani I., Giamarellou H. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J. Chemother. 2003, 15:235-238.
15. Payne D.J., Gwynn M.N., Holmes D.J., Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 2007, 6:29-40.
16. Li J., Milne R.W., Nation R.L., Turnidge J.D., Coulthard K., Valentine J. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob. Agents Chemother. 2002, 46:3304-3307.
17. Li J., Coulthard K., Milne R., Nation R.L., Conway S., Peckham D., Etherington C., Turnidge J. Steady-state pharmacokinetics of intravenous colistinmethanesulphonate in patients with cystic fibrosis. J. Antimicrob. Chemother. 2003, 52:987-992.
18. Ma Z., Wang J., Gerber J.P., Milne R.W. Determination of colistin in human plasma, urine and other biological samples using LC-MS/MS. J. Chromatogr. B 2007, 862:205-212.
19. Jansson B., Karvanen M., Cars O., Plachouras D., Friberg L.E. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. J. Pharm. Biomed. Anal. 2009, 49:760-767.
20. Dotsikas Y., Markopoulou C.K., Koundourellis J.E., Loukas Y.L. Validation of a novel LC/MS/MS method for the quantitation of colistin A and B in human plasma. J. Sep. Sci. 2010, 34:37-45.
21. Gobin P., Lemaître F., Marchand S., Couet W., Olivier J.C. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob. Agents Chemother. 2010, 54:1941-1948.
22. European Medicines Agency (EMA), Committee for Medicinal Products For Human Use (CHMP), Guideline on Validation of Bioanalytical Methods, Doc. Ref EMEA/CHMP/EWP/192217/2009.
23. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Validation of Analytical Procedures, Text and Methodology Q2(R1) 2005.